1. Clinical & Scientific Overview
Alpha-Arbutin (TIP-MED-000613, Reference Code [COS-09]) is classified under
Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Biosynthetic Hydroquinone-Alpha-D-Glucopyranoside Tyrosinase Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Cosmetic ingredient permitted up to 2.0% (face) under Cosmetics Rules, 2020 / EU-aligned BIS standards; free Hydroquinone is strictly a Schedule H drug prohibited in cosmetics..
INCI Standard: Alpha-Arbutin (IS 4707 / Cosmetics Rules, 2020 Compliant)
Up to 2.0% max in facial creams/serums and 0.5% in body lotions; pH 4.5–6.5
Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance
Alpha-ArbutinBiosynthetic Hydroquinone-Alpha-D-Glucopyranoside Tyrosinase Inhibitor
Up to 2.0% max in facial creams/serums and 0.5% in body lotions; pH 4.5–6.5
Irritation, Sensitisation & Photoprotection Considerations: At acidic pH (<3.5) or temperatures >40°C, alpha-arbutin can hydrolyse to release trace free hydroquinone (which is banned in cosmetics due to exogenous ochronosis risk); maintain formulation pH 4.5–6.5 with sodium metabisulfite/citrate buffer.
Chemical Stability & Formulation Incompatibilities: Incompatible with strong acids, alkalis, and iron contamination; must never claim 'skin whitening' or 'bleaching' under the Drugs and Magic Remedies Act / ASCI guidelines.
Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Cosmetic ingredient permitted up to 2.0% (face) under Cosmetics Rules, 2020 / EU-aligned BIS standards; free Hydroquinone is strictly a Schedule H drug prohibited in cosmetics.
3. Mechanism of Action & Pharmacodynamics
Reversibly and competitively inhibits epidermal melanosomal tyrosinase activity via structural homology to L-tyrosine without melanocyte cytotoxicity; 10-fold more potent and stable than beta-arbutin.
4. Therapeutic Indications & Evidence-Supported Uses
- Cosmetic brightening of solar lentigines and post-inflammatory hyperpigmentation marks
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: Up to 2.0% max in facial creams/serums and 0.5% in body lotions; pH 4.5–6.5
Administration & Meal Timing: External topical use only (Up to 2.0% max in facial creams/serums and 0.5% in body lotions; pH 4.5–6.5). Incompatible with strong acids, alkalis, and iron contamination; must never claim 'skin whitening' or 'bleaching' under the Drugs and Magic Remedies Act / ASCI guidelines.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Not applicable (topical external cosmetic use).
7. Contraindications, Precautions & High-Risk Warnings
- Known allergic contact dermatitis or hypersensitivity to Alpha-Arbutin
- Application to open wounds, abraded skin, or acute infectious dermatoses
- At acidic pH (<3.5) or temperatures >40°C, alpha-arbutin can hydrolyse to release trace free hydroquinone (which is banned in cosmetics due to exogenous ochronosis risk); maintain formulation pH 4.5–6.5 with sodium metabisulfite/citrate buffer.
Key Clinical Precautions: At acidic pH (<3.5) or temperatures >40°C, alpha-arbutin can hydrolyse to release trace free hydroquinone (which is banned in cosmetics due to exogenous ochronosis risk); maintain formulation pH 4.5–6.5 with sodium metabisulfite/citrate buffer.
8. Adverse Effects Profile
- At acidic pH (<3.5) or temperatures >40°C, alpha-arbutin can hydrolyse to release trace free hydroquinone (which is banned in cosmetics due to exogenous ochronosis risk); maintain formulation pH 4.5–6.5 with sodium metabisulfite/citrate buffer.
- At acidic pH (<3.5) or temperatures >40°C, alpha-arbutin can hydrolyse to release trace free hydroquinone (which is banned in cosmetics due to exogenous ochronosis risk); maintain formulation pH 4.5–6.5 with sodium metabisulfite/citrate buffer.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Incompatible with strong acids, alkalis, and iron contamination; must never claim 'skin whitening' or 'bleaching' under the Drugs and Magic Remedies Act / ASCI guidelines.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Incompatible with strong acids, alkalis, and iron contamination; must never claim 'skin whitening' or 'bleaching' under the Drugs and Magic Remedies Act / ASCI guidelines.
Pharmacist Patient Counselling Points:
- Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
- Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
- Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.
Storage, Stability & Dispensing Safeguards: Incompatible with strong acids, alkalis, and iron contamination; must never claim 'skin whitening' or 'bleaching' under the Drugs and Magic Remedies Act / ASCI guidelines.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.
Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.